IGX Archives - Page 7 of 8

Developments

IntelGenx files U.S. patent application for oil-based active ingredients

IntelGenx (TSX-V:IGX; OTCQX:IGXT) filed a new non-provisional patent application with the U.S. Patent and Trademark Office, covering a newly developed platform that enables incorporation of oil-based (lipophilic) active...

April 16, 2019

Developments

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

IntelGenx’s (TSX-V:IGX) (OTCQX:IGXT) Montelukast VersaFilm program received positive and constructive feedback from the scientific community at the 14thInternational Conference on Alzheimer’s & Parkinson’s Diseases...

April 8, 2019

Developments

IntelGenx among few Quebec companies leading cannabis edibles market

An article recently published in La Presse highlighted Montreal’s IntelGenx (OTCQX:IGXT; TSXV:IGX) as one of the few Quebec-based companies at the forefront of the cannabis edibles market. Of some 150 Health Canada...

April 3, 2019

Developments

IntelGenx to receive Japanese patent for RIZAPORT VersaFilm

IntelGenx (TSXV:IGX; OTCQX:IGXT) received a Decision to Grant notice from the Japanese Patent Office (JPO) for the VersaFilm formulation used in its thin oral film RIZAPORT product for the treatment of acute migraines...

February 11, 2019

Executive Moves

IntelGenx names Rodolphe Obeid as VP of operations

IntelGenx Technologies (TSXV:IGX; OTCQX:IGXT) appointed Dr. Rodolphe Obeid as VP of operations to oversee manufacturing, packaging, facilities and maintenance, production planning and supply chain management.

February 8, 2019

Developments

FDA performs pre-approval inspection of IntelGenx plant for RIZAPORT

The FDA has performed a pre-approval inspection of IntelGenx’s (TSXV:IGX; OTCQX:IGXT) Health Canada-certified cGMP manufacturing facility in Montreal in connection with the company’s NDA for RIZAPORT, a VersaFilm oral...

January 30, 2019

Developments

IntelGenx updates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (TSXV:IGX; OTCQX:IGXT) updated its Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD). To date, seven study sites across Canada have randomized eight subjects...

January 23, 2019

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX: IGXT) 505(b)(2) NDA resubmission of RIZAPORT oral soluble film 10 mg for the treatment of acute migraines. The FDA also assigned a Prescription Drug User Fee Act (PDUFA)...

November 20, 2018

Developments

IntelGenx partner, Insud Pharma, submits ANDA for generic buccal product

IntelGenx’s (TSXV:IGX; OTCQX:IGXT) partner, Insud Pharma (formerly Chemo Group), submitted an abbreviated new drug application (ANDA) with the FDA for a generic buccal film product. “The filing of an ANDA for this...

October 4, 2018

Developments

IntelGenx receives Canadian patent notice for Loxapine VersaFilm

The Canadian Intellectual Property Office (“CIPO”) has issued a notice of allowance for IntelGenx’s (TSXV:IGX; OTCQX:IGXT) first Canadian patent application for its VersaFilm technology. Entitled, “Loxapine Film Oral...

July 5, 2018

Tag - IGX

IntelGenx files U.S. patent application for oil-based active ingredients

IntelGenx receives positive feedback for Montelukast VersaFilm at ADPD conference

IntelGenx among few Quebec companies leading cannabis edibles market

IntelGenx to receive Japanese patent for RIZAPORT VersaFilm

IntelGenx names Rodolphe Obeid as VP of operations

FDA performs pre-approval inspection of IntelGenx plant for RIZAPORT

IntelGenx updates Phase 2a Montelukast VersaFilm trial in AD

FDA accepts IntelGenx NDA resubmission for RIZAPORT

IntelGenx partner, Insud Pharma, submits ANDA for generic buccal product

IntelGenx receives Canadian patent notice for Loxapine VersaFilm

General

More